188 citations,
October 2014 in “Thyroid” Dabrafenib was effective and well tolerated in treating thyroid cancer with a specific mutation.
173 citations,
July 2012 in “British Journal of Dermatology” Dabrafenib can cause skin growths and sometimes low-grade skin cancer.
6 citations,
April 2013 in “Current Dermatology Reports” Dermatologists are crucial for managing skin side effects in metastatic melanoma patients using vemurafenib and ipilimumab.
3 citations,
June 2021 in “PLOS ONE” A topical BRAF inhibitor, vemurafenib, can speed up wound healing and promote hair growth, especially in diabetic patients.
1 citations,
August 2018 in “Journal of The American Academy of Dermatology” Patients with melanoma who saw dermatologists and were from higher-income areas were more likely to have follow-up visits, which was linked to lower mortality.